U.S. Markets close in 5 hrs 58 mins
  • S&P 500

    -1.20 (-0.03%)
  • Dow 30

    -30.20 (-0.09%)
  • Nasdaq

    -3.58 (-0.03%)
  • Russell 2000

    +6.59 (+0.36%)
  • Crude Oil

    +1.62 (+2.10%)
  • Gold

    +10.90 (+0.62%)
  • Silver

    +0.36 (+1.72%)

    +0.0004 (+0.0414%)
  • 10-Yr Bond

    +0.0490 (+1.32%)
  • Vix

    +0.25 (+1.13%)

    +0.0013 (+0.1090%)

    -0.3370 (-0.2426%)

    +171.25 (+1.06%)
  • CMC Crypto 200

    -1.42 (-0.37%)
  • FTSE 100

    +50.41 (+0.67%)
  • Nikkei 225

    -134.99 (-0.48%)

Great news for Harvard Bioscience, Inc. (NASDAQ:HBIO): Insiders acquired stock in large numbers last year

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Harvard Bioscience, Inc. (NASDAQ:HBIO), it sends a favourable message to the company's shareholders.

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

Check out our latest analysis for Harvard Bioscience

The Last 12 Months Of Insider Transactions At Harvard Bioscience

Notably, that recent purchase by President James Green was not the only time they bought Harvard Bioscience shares this year. They previously made an even bigger purchase of US$147k worth of shares at a price of US$3.78 per share. That means that even when the share price was higher than US$3.17 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

While Harvard Bioscience insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!


There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insiders At Harvard Bioscience Have Bought Stock Recently

It's good to see that Harvard Bioscience insiders have made notable investments in the company's shares. Overall, two insiders shelled out US$274k for shares in the company -- and none sold. That shows some optimism about the company's future.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 12% of Harvard Bioscience shares, worth about US$16m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At Harvard Bioscience Tell Us?

The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Given that insiders also own a fair bit of Harvard Bioscience we think they are probably pretty confident of a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. While conducting our analysis, we found that Harvard Bioscience has 2 warning signs and it would be unwise to ignore them.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here